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To the Editor:
Many aspects of the scientific, economic and political
discussions on the benefit of new medicines, for which
modern insulins are a pivotal example, resonate in the
recent Editorial by Holleman and Gale [1]. In this letter we
comment on some errors in this contribution and raise
questions on some of the authors’ assumptions. As space is
restricted, we are unable to provide a comprehensive review
of the evidence.
Facts
Share of analogues out of total insulin prescriptions The
use of insulin analogues is significantly lower in Germany
than in other large European countries [2]. In 2006,
analogues made up 40.6% of the insulin prescriptions in
Germany, compared with 75.6% in France, 87.6% in the
UK, 61.7% in Spain, 46.0% in Italy, 91.2% in Sweden and
71.4% in Austria. In 2007, almost two out of every three
German insulin patients were treated with human insulin
and not analogues [2].
Reaction to the German Institute for Quality and Efficiency
in Healthcare report on short-acting insulin analogues in
type 2 diabetes It is not correct that the industry did not
dispute the results provided by the German Institute for
Quality and Efficiency in Healthcare (IQWiG) on short-
acting insulin analogues in type 2 diabetes. Sanofi-Aventis,
like other manufacturers, has criticised the IQWiG assess-
ment as being erroneous and biased [3] and the conse-
quences drawn from it as unbalanced [4], with the detailed
review provided by Sanofi-Aventis on the assessment in the
public domain [3]. In addition, our company has initiated
legal action against the authorities’ decision to no longer
reimburse the costs of prescriptions for short-acting
analogues for type 2 diabetic patients. Sanofi-Aventis’
decision to give rebates to statutory sick funds was made
to ensure continuity of care for patients.
IQWIG reports regarding insulin analogues Holleman and
Gale suggest that further to the lack of benefits of short-
acting insulin analogues reported by IQWiG, similar
findings are likely for the long-acting analogues.
IQWiG results on short-acting analogues in type 1
diabetes have been discussed by scientific experts in a
hearing initiated by the Gemeinsamer Bundesausschuss
(G-BA, [Joint Federal Committee]), the German authority
responsible for reimbursement. It became clear that impor-
tant benefits had not been identified by IQWiG (e.g. use in
children) [5]. Regarding long-acting analogues, IQWiG
recently amended its report plan, almost 2 years after its
initial publication [6, 7], following the new law making it
mandatory for IQWiG to follow international standards.
The amended plan has been subject to a scientific hearing
and its final version is currently pending.
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The authors of the Editorial concede that there are ‘limited’
benefits of glargine vs NPH insulin in terms of ‘a1 5 –20%
reduction in hypoglycaemia, mainly at night’. They subse-
quently state that HbA1c levels and hypoglycaemia require
combined analysis. We would like to refer to a new meta-
analysis on patient-level data that has examined precisely
this [8]. The authors of the meta-analysis conclude that the
benefit of glargine vs NPH is in the range of 25–30% for
confirmed and severe hypoglycaemic events. In studies
with more aggressive titration schemes, the superiority of
glargine vs NPH with regard to hypoglycaemia even
reaches 40–50%. The same investigation also provides
evidence of improved rates of symptomatic hypoglycaemia
for glargine vs NPH. Because the risk of hypoglycaemia is
a significant barrier to reaching target HbA1c [9], the
benefits of glargine vs NPH are obvious in this area.
Assumptions
Evidence-based medicine Holleman and Gale call for
evidence-based medicine as the ultimate authority with
regard to insulin analogues. They regret ‘with some despair’
the non-availability of double-blind comparative trials as the
‘only one fully objective’ way of drawing conclusions,
although they state earlier in their article that these trials
were often hardly possible on the grounds that NPH and
glargine can easily be distinguished. We would like to draw
the reader’s attention to the broader definition of evidence-
based medicine established by key scientists in this area.
Sackett et al. point out that even when randomised trials are
absent or impossible, evidence-based medicine should be
applied, stating that ‘if no randomised trial has been carried
out for our patient’s predicament, we must follow the trail to
the next best external evidence and work from there’ [10].
According to Haynes [11], evidence becomes relevant in
clinical practice when the patient’s circumstances are
established, related to efficacy, effectiveness and efficiency
of treatment options, and the likely consequences of each
option are taken into account. Thus, the task is not to
choose between eminence-based and evidence-based med-
icine, but to identify the best available evidence for the
questions asked. To this end, there is more evidence to be
considered than that provided by double-blind, randomised
clinical trials alone. We propose to discuss the question of
evidence for benefit of insulin analogues with pragmatic
responsibility for patients rather than in the spirit of the
search for the Holy Grail.
Will human insulin be withdrawn from the market? In the
Editorial the authors discuss potential interest in the
industry to withdraw human insulin from the market. Such
a move would be unethical in light of the fact that certain
human insulin formulations cannot be substituted by insulin
analogues (e.g. formulations for pediatric use), and human
insulin remains an important element in the therapeutic
portfolio of physicians. We hereby would like to confirm
the commitment of Sanofi-Aventis to supplying the full
range of human insulin preparations to the German market
in the practically foreseeable future, in the interest of
patients and caregivers.
Price and cost of insulin therapies Holleman and Gale
suggest a ‘resolution that drug prices should be linked to
evidence of benefit’, implying that the higher price of
glargine vs NPH (in the presence of low benefit, according
to their view) is socially unacceptable when resources for
healthcare are limited. They suggest that prices of ana-
logues should be equal to that of human insulin.
We profoundly object to this route of reasoning—the
cost of a chosen therapeutic intervention is not reflected by
the public price of one of the employed drugs. Specifically
in insulin-based therapy, resource utilisation includes
additional factors, e.g. blood sugar monitoring, injection
devices and needles, physician visits, rebates. If such
factors are taken into account, pharmacoeconomic studies
in the German context reveal that glargine-based therapies
are cost-equal or even cheaper than human insulin regimens
at today’s price level [12].
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